Related Experiment Videos
Effects of beta blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects
1Department of Medicine, Ostra Hospital, Götenborg University, Sweden.
Insights
Beta-blocker therapy significantly reduces mortality and sudden death in acute myocardial infarction patients with left ventricular dysfunction (LVD). These findings suggest broad benefits for LVD patients who can tolerate beta blockade.
Area of Science:
- Cardiology
- Pharmacology
Background:
- 44 randomized trials on beta blockade in acute myocardial infarction (AMI) have been reported.
- Trials excluded patients with moderate-to-severe left ventricular dysfunction (LVD).
- Some trials included high-risk patients with mild LVD or compensated heart failure.
Purpose of the Study:
- To evaluate the efficacy and safety of beta-blocker treatment in AMI patients with LVD.
- To assess the impact of beta blockers on mortality and sudden death in this patient subgroup.
Main Methods:
- Analysis of data from existing randomized trials of beta blockade in AMI.
- Focus on patient subgroups with varying degrees of LVD.
- Comparison of outcomes between beta-blocker and placebo groups.
Main Results:
- Beta-blocker treatment was well tolerated in patients with LVD during acute and long-term phases.
- Mortality was reduced by 20-30% in LVD patients treated with beta blockers compared to placebo.
- Significant reductions (43-47%) in sudden death were observed in LVD patients on beta blockers.
Conclusions:
- Beta-blocker therapy offers significant survival benefits for acute myocardial infarction patients with LVD.
- The absolute benefit in lives saved is greater in LVD patients due to their higher baseline mortality.
- All LVD patients who can tolerate beta blockade should be considered for this treatment.
Abstract:
At least 44 randomized trials of beta blockade in acute myocardial infarction have been reported. All of these trials excluded patients with moderate-to-severe clinical signs of acute left ventricular dysfunction (LVD). Several of the larger trials did include high-risk patients with a history of compensated heart failure or with symptoms and signs suggesting mild LVD. Data from these trials indicate that beta-blocker treatment was well tolerated by patients with LVD, both in the acute phase of myocardial infarction and during long-term follow-up treatment. Further, data for LVD patients indicate that mortality in the beta-blocker group was reduced by 20-30% when compared with the placebo group. A similar mortality reduction was obtained for the entire patient population in the trials. Because of the high mortality among patients with mild LVD, the absolute gain in numbers of lives saved per 100 patients treated with beta blockers is even larger than that in patients without LVD. Data from two long-term trials indicate marked (47% and 43%) reductions in the likelihood of sudden death among LVD patients treated with beta blockers. These results suggest that all patients with LVD who can tolerate beta blockade may benefit from treatment with these agents.